115378-21-7

Basic information

• Product Name: methyl 2-amino-5-bromo-3-methoxybenzoate
• Synonyms: methyl 2-amino-5-bromo-3-methoxybenzoate;2-Amino-5-bromo-3-methoxy-benzoic acid methyl ester
• CAS NO: 115378-21-7
• Molecular Formula: C₉H₁₀BrNO₃
• Molecular Weight: 260.0846
• Mol File: 115378-21-7.mol
• Article Data: 10

Chemical Properties

• Melting Point: 54.5-55 °C
• Boiling Point: 314.4±37.0 °C(Predicted)
• Appearance: /
• Density: 1.531±0.06 g/cm3(Predicted)
• PKA: 1.70±0.10(Predicted)
• CAS DataBase Reference: methyl 2-amino-5-bromo-3-methoxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-amino-5-bromo-3-methoxybenzoate(115378-21-7)
• EPA Substance Registry System: methyl 2-amino-5-bromo-3-methoxybenzoate(115378-21-7)

Safety Data

• Hazardous Substances Data: 115378-21-7(Hazardous Substances Data)

Usage

General Description

Methyl 2-amino-5-bromo-3-methoxybenzoate is a chemical compound with the molecular formula C9H10BrNO3. It is a derivative of benzoic acid and contains a methyl ester, an amino group, a bromine atom, and a methoxy group. This chemical is commonly used in the pharmaceutical industry for the synthesis of novel drug compounds due to its potential biological activities. It has been studied for its anti-inflammatory and analgesic properties, making it a valuable compound for drug discovery and development. Additionally, it has been explored for its potential use in the treatment of various diseases and medical conditions.

Upstream product

• 4920-80-3 3-methoxy-2-nitrobenzoic acid 
• 5307-17-5 methyl 3-methoxy-2-nitrobenzoate 
• 4771-47-5 3-chloro-2-nitro-benzoic acid 
• 602-00-6 3-hydroxy-2-nitrobenzoic acid 
• 5121-34-6 methyl 2-amino-3-methoxybenzoate 
• 115378-20-6 3-methoxy-2-pivalamidobenzoic acid 
• 90-04-0 2-methoxy-phenylamine 
• 33768-49-9 N-(2-methoxyphenyl)pivalamide 
• 3177-80-8 2-amino-3-methoxybenzoic acid 

Downstream Products

• 864292-36-4 6-bromo-2,4-dichloro-8-methoxyquinazoline 
• 1415470-79-9 (2S,3R,4R,5S,6R)-2-(6-(4-ethylbenzyl)-7-chloro-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol 
• 1415470-82-4 (2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-ethylbenzyl)chroman-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1415470-83-5 (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1415467-76-3 5-bromo-2-chloro-3-methoxybenzoic acid 

Relevant articles and documents

Discovery of GCC5694A: A potent and selective sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes

Sodium-dependent glucose co-transporter 2 (SGLT2) has emerged as a promising drug target for the treatment of type 2 diabetes, and recently, several SGLT2 inhibitors have been approved for clinical use. A series of molecules with a C-aryl glucoside scaffo

METHOD FOR PRODUCING DIPHENYLMETHANE DERIVATIVE

The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which

As a new polyphenylenepolymethylenepolyisocyanate deriv. SGLT2 inhibitor

A compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney is disclosed. A pharmaceutical composition including the compound as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes is disclosed. A method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound is provided.